FDA advisors boost Boehringer Ingelheim's antithrombotic drug
This article was originally published in Scrip
Executive Summary
A US FDA advisory committee voted 9-0 that Boehringer Ingelheim's Pradaxa (dabigatran) should be approved for the reduction of stroke and non-central nervous system systemic embolism in patients with non-valvular atrial fibrillation (AF). The recommendation has moved the company one step closer in a heated race to put warfarin alternatives for stroke prevention on the market.